- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02110849
Prostate Cancer Parameters for Patients Receiving Proton Treatment
Longitudinal Study for the Evaluation of Safety and Efficacy Parameters in Prostate Cancer Patients Treated at IU Health Proton Therapy Center (IUHPTC)
Studieoversikt
Detaljert beskrivelse
The major purpose of this study is to analyze side effects experienced and self-reported by prostate cancer patients undergoing proton radiation therapy at IUHPTC. With the information collected, the investigators will establish pre-existing conditions before proton treatment and measure side effects after treatments that are not related to the pre-existing conditions. Also, to compare long-term side effects for patients who are treated with hormone suppression therapy along with their proton therapy to those patients who do not get treated with hormone suppression therapy. This information will help doctors better understand the side effects experienced and may help provide valuable information for future patients making decisions regarding their treatment options.
Finally, to develop a database of information regarding the treatment and outcomes for patients with prostate cancer in order to improve care of patients with this type of cancer.
Studietype
Kontakter og plasseringer
Studiesteder
-
-
Indiana
-
Bloomington, Indiana, Forente stater, 47408
- Iu Health Proton Therapy Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Subjects must have histologically or cytologically confirmed adenocarcinoma of the prostate and are scheduled to receive proton radiation treatment at IUHPTC.
- Subjects with any stage or grade of tumor will be allowed including proton salvage therapy in the context of a rising PSA after surgery and a negative metastatic work-up.
- Prior use of Lupron therapy or a similar agent is allowed. Use of Lupron or similar agent must be for ≤ 6 months prior to enrollment.
- Use of Casodex and agents in the same drug class is allowed. Age is ≥ 18 years at the time of consent.
- The ability to understand and willingness to sign an informed consent and authorization for the release of health information.
Exclusion Criteria:
-Evidence of distant metastases at the time of enrollment.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Case-Control
- Tidsperspektiver: Potensielle
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
Prostate Cancer Patients
Prostate cancer patients who received proton radiation therapy
|
Proton Therapy for Prostate Cancer
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
To prospectively collect a composite of toxicity events on patients who treated with proton therapy for prostate cancer using the IUHPTC technique for the evaluation of toxicity and efficacy of this treatment technique.
Tidsramme: 12 months
|
A collection of toxicity events of proton therapy, evaluate the long-term side effects of hormone suppression vs. non-hormone suppression and documents the clinical benefits this therapy in regards to urinary, sexual and gastrointestinal issues. To do this the investigators will use the following standard of care data collection forms that include; the International Index of Erectile Function (Attachment 1), the American Urological Association Symptom Index (Attachment 2) and the Radiation Therapy Initial Nursing Assessment (Attachment 3), The prostate preexisting conditions review (attachment 4) and the prostate side effects review (attachment 5). Other clinical data such us demographics, vitals, previous treatments, PSA(prostate specific antigen/Hormone results, follow up data, as described in the protocol schedule of events, will be collected as per routine standard of care. |
12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Jeffery Buchsbaum, MD, Indiana University Proton Therapy Center
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IUHPTC-03
- IRB #1206008885 (Annen identifikator: Indiana University)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Proton
-
National Taiwan University HospitalFullført
-
Mayo ClinicNational Cancer Institute (NCI)RekrutteringAnatomisk stadium I brystkreft AJCC v8 | Anatomisk stadium II brystkreft AJCC v8 | Anatomisk stadium III brystkreft AJCC v8Forente stater
-
Emory UniversityNational Cancer Institute (NCI)Har ikke rekruttert ennåResektabelt ikke-småcellet lungekarsinomForente stater
-
Washington University School of MedicineThe Foundation for Barnes-Jewish HospitalRekruttering
-
University of CincinnatiAktiv, ikke rekrutterende
-
Abramson Cancer Center at Penn MedicinePatient-Centered Outcomes Research InstituteAktiv, ikke rekrutterende
-
Odense University HospitalHar ikke rekruttert ennåSkrøpelighet | Ikke-småcellet lungekreft stadium III | Bivirkning av strålebehandling
-
Mayo ClinicNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeTilbakevendende hepatocellulært karsinom | Stage III hepatocellulært karsinom AJCC v8 | Stage II hepatocellulært karsinom AJCC v8 | Stage I hepatocellulært karsinom AJCC v8Forente stater
-
Abramson Cancer Center at Penn MedicineNational Heart, Lung, and Blood Institute (NHLBI)Aktiv, ikke rekrutterendeBrystkreft | KardiotoksisitetForente stater
-
Massachusetts General HospitalJanssen PharmaceuticaFullført